Cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), frequently presents with severe pruritus.1,2 Interleukin-31 (IL-31), a T helper type 2 cytokine, elevated in the serum and skin of patients with CTCL may be associated with pruritus.3,4 Nemolizumab, a monoclonal antibody targeting the IL-31 receptor alpha subunit, is approved for prurigo nodularis and atopic dermatitis and increasingly used off-label for CTCL-associated itch.5 Routine effectiveness...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile